MAP2K7 and melanoma: MEK inhibition in melanomas and NSCLC leads to increased expression of immunogenic antigens, upregulation of immune-critical molecules, including HLA class I, and increased immune responses in the form of CD8+ T cells in the microenvironment (39–41).